DIABETES IN ADOLESCENTS AND YOUNG ADULTS. Rasa VERKAUSKIENĖ LITHUANIAN UNIVERSITY OF HEALTH SCIENCES
|
|
- Gerald Reeves
- 5 years ago
- Views:
Transcription
1 DIABETES IN ADOLESCENTS AND YOUNG ADULTS Rasa VERKAUSKIENĖ LITHUANIAN UNIVERSITY OF HEALTH SCIENCES EASD Postgraduate Course 2017
2 TYPE 1 in ADOLESCENCE and YOUNG ADULTS Major advances past 30 yrs No reduction in acute complications Potential benefits of improved glycemic control reaching a minority of patients
3 TARGETS Parameter HbA1c Blood glucose Target Level 7.5% Pre-prandial : mmol/l Bedtime : mmol/l BP* LDL-C HDL-C TG BMIª <95 th percentile <2.6 mmol/l >1.1 mmol/l <1.7 mmol/l <95 th percentile *Adjusted for age, sex, and height; ªAdjusted for age and sex ISPAD Guidlines 2014, ADA, Diabetes Care 2017
4 TYPE 1 DIABETES EXCHANGE Struggles with Glycemic Control n = 16,791 Miller at el: Diabetes Care
5 TYPE 1 DIABETES EXCHANGE Glycemic Control (2015) n = 16,791 HbA1c Goal = <7.5% < 18 yr HbA1c Goal = <7.0% Miller at el: Diabetes Care
6 Centres of Reference ( ): 48 centres from 33 countries over 5 continents, > patients
7 Procentai % n ,9 66, , , ,2 37,4 62,7 33,3 0 < 7,5 7, ,1 11,4 > <6 6-<12 12-<18 18-<25 Age groups
8 RATES OF DKA AND SEVERE HYPOGLYCEMIA IN TYPE 1 DIABETES EXCHANGE
9 WHY IS IT SO HARD? BARRIERS TO SUCCESS Burn out Inadequate motivation and support Family Healthcare team Fear of and actual hypoglycemia Weight gain Need for frequent BG monitoring Insulin pharmacokinetics
10 In addition, in adolescence Endocrine changes leading to increased insulin resistance Erratic meal and exercise pattern Poor adherence to treatment regiments omission of insulin Eating disorders Hazardous and risk taking behavior
11 Adolescence period For all young people, adolescence is a period of biological, social and emotional change, in which they work through four developmental tasks: To consolidate their identity To achieve independence from their parents To establish adult relationships outside their families To find a vocation
12 Differences of the brain Adolescence Limbic >>>Frontal lobe Frontal lobe develops in Girls years old Boys years old Emerging adulthood y y.
13 Attitudes of adolescents and emerging adults Autonomy To be as different from caring adults as possible Affiliation To be admired by peers
14 Omission of insulin to control weight Omission of insulin Glucose continues to circulate in the blood Glucosuria Body forced to obtain energy from fat and muscle stores Rapid weight loss
15 Prevalence rates of insulin omission Prevalence of insulin omission (%) Age range (yr) Number and sex Reference Female Male Female Male Colton et al. 26,2 4, Wisting et al Jones et al Rodin et al Neumark-Sztainer et al Rydall et al Stancin et al Philippi et al.
16 HbA1c fluctuations Insulin omission is characterized by both high HbA1c levels and wide fluctuations from visit to visit. (3) Warning sign - high HbA1c levels. (2)
17 Intentional insulin omission Intentional insulin omission has recently been called as diabulimia. (2) It can be: inappropriate compensatory feature of bulimia nervosa component of other specified eating disorder (when insulin omission occurs without binge eating).(1) Pinhas-Hamiel, World Journal of Diabetes Colton et al, Diabetes Spectrum 2009
18 Eating disorders and T1DM Meta-analysis Anorexia nervosa in T1DM patients was not significantly different from that of controls (0.27 vs 0.06%).(1) Bulimia nervosa in T1DM females has significantly higher prevalence than in not diabetics (1.73 vs 0.69%, p < 0.05).(1) T1DM adolescents are at 2.4 times risk of developing bulimia nervosa compared to healthy ones.(3) Overall prevalence of eating disorders: 7.0% in T1DM, compared with 2.8% in individuals without T1DM.(1) Pinhas-Hamiel, World Journal of Diabetes Eating disorders in adolescents with Type 1 Diabetes
19 Eating disorders: Complications Result in poor metabolic control and cause short and long-term complications and leads to higher hospitalication rates.(3) Short term complications: Insulin omission is associated with recurrent events of DKA, disturbed eating behavior is associated with recurrent episodes of severe hypoglycemia.
20 Eating disorders: Complications 4 year follow-up study Retinopathy: 86% of girls with T1DM + severe ED 24% of girls with T1DM, but without ED (p=0.004)(3) 11 year follow-up study of females with T1DM (mean age - 45 yr; mean diabetes duration - 28 years): Nephropathy: 25% of those with insulin omission 10% of those without insulin omission (p < 0.01) foot problems 25% of those with insulin omission 12% of those without insulin omission (p < 0.05)(9) Eating disorders in adolescents with Type 1 Diabetes
21 Eating disorders: Mortality Mortality rates per 1000 person years 2.2 in girls with T1DM, 7.3 in girls with ED 34.6 in girls with both T1DM and ED. During an 11-year period, self-reported insulin restriction at baseline increased the relative risk of death by 3.2 times in women; Women with ED died younger than those without ED (aged 44 vs 58 years, P < 0.01). (9) Pinhas-Hamiel, World Journal of Diabetes Goebel-Fabbri et al, Diabetes Care 2008
22 Adolescents: care issues Education Glycemic targets Insulin therapy Glucose monitoring Nutrition Hypoglycemia DKA Alkohol, Smoking, Drugs Sexual Health Driving Psychology Comorbidities Complications Transition to Adult care
23 Education: identifying the components of care that are unique to adolescents Psychoeducational interventions: modest effect on psychological outcomes, but no effect on HbA1c Developing trusting relationship Clarify priorities and set achievable targets Having an index of suspicion of mental health problems (the HEADS technique) Encouraging the adolescent to participate in making decisions about diabetes management Offering a variety of educational opportunities (CD/videos, apps, games, text messages, peer involvement, group learning ) Helping parents in their changing role from full responsibility toward a gradual transition to cooperative care
24 Parental involvement
25 Education: identifying the components of care that are unique to adolescents Healthcare providers should regularly initiate discussions with adolescents and their families about School Diabetes camp Psychological issues Substance use Contraception Career choices Driving
26 HbA1c and motor vehicles crash Motor vehicles accident - one of the leading causes of deaths among teenagers in USA - 1 of 3 deaths. HbA1c <= 6.9 associated with 3X higher risk of accident compared to HbA1c >= 9.0
27 HOW TO MINIMIZE RISK OF HYPOGLYCEMIA WHILE IMPROVING GLYCEMIC CONTROL? Address hypoglycemia at each visit Education Frequent BG monitoring, CGMS Physiologic flexible insulin regimens, CSII Exercise strategy Bedtime strategy, check overnight BG awareness training (BGAT) Counsel about effects of alcohol New Insulin analogs Individualize glycemic targets Ongoing professional support
28 An ultra-long glucose-lowering effect of beyond 40 hours Type 1 diabetes (n=66) Nocturnal hypoglycaemia 25% Figure shows mean and individual blood glucose profiles following once-daily s.c. dosing of IDeg (0.6 U/kg) for 8 days Kurtzhals P et al., Diabetes 2011
29 GIR (mg/kg/min) IAsp serum conc. (pmol/l) FA LAP kick-off PL&CZ Faster aspart via s.c. injection (PK/PD) Compared with insulin aspart, faster aspart has: Faster aspart Insulin aspart Twice as fast onset of appearance in the bloodstream Two-fold higher insulin exposure within the first 30 min Time (min) 6 >50% greater insulin action within the first 30 min 4 2 GIR, glucose infusion rate; IAsp, insulin aspart; SC, subcutaneous Heise T et al. Diabetes 2016;65(S1):A Time (min)
30 PPG increment (mmol/l) PPG increment (mg/dl) onset 1: PPG increment at Week 26 Meal test. Faster aspart (mealtime) vs insulin aspart (mealtime) 7 1h ETD: mmol/l [95%CI: -1.65; -0.71] Week 26 2h ETD: mmol/l [95%CI: -1.29; -0.04] 126 Faster aspart (mealtime) Insulin aspart (mealtime) * * Bolus dose 0.1 U/kg Time (min) 0 *Statistically significant Error bars: ± standard error (mean). The conversion factor between mmol/l and mg/dl is PPG, postprandial plasma glucose; ETD, estimated treatment difference [Faster aspart (mealtime) insulin aspart (mealtime)] for PPG changes from baseline. Russell-Jones D et al. Diabetes 2016;65(S1):A77
31 HbA1c: pumps vs. MDI Doyle (Boland) E. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care. 2004;27:
32 Hypoglycemia: pumps vs. MDI Rudolph JW, Hirsch IB. Assessment of Therapy with Continuous Subcutaneous Insulin Infusion in an Academic Diabetes Clinic. Endocr Pract. 2002;8:401-5.
33 Small kids Teenagers with down fenomenon Recurrent severe hypoglycemia Brittle diabetes Large glycemic variability Micro-, macrovascular complications Pregnancy Diabetes Care 2007; 30(6)
34 Sensor augmented insulin pump therapy
35 Mean HbA1c by CGM use P<0.001 P<0.001 P<0.001
36 Artificial Pancreas or Closed Loop system Continuous glucose monitoring Insulin pump Control algorithm
37 Alcohol Adopting realistic advisory approach Information on the effects of alcohol Inhibiting gluconeogenesis risk of late hypoglycemia Hypoglycemia may be confused with intoxication inform friends Eat carbs Maintain good hydration Check blood glucose before bed ISPAD Clinical Practice Consensus Guidelines 2014 Compendium
38 Smoking Inform on increased risk of cardiovascular complications Help to quit (nicotin-patches, cognitive-behavioral therapies, drugs, ) Recognize that cannabis may alter eating habits (increased apetite during and decreased after smoking) May reduce motivation to maintain good metabolic control.
39 Illicit drugs May alter brain function Increase the rsik of mistakes and mishaps with diabetes management
40 Australian study: interview of 504 adolescents with type 1 diabetes 77% tried drugs at least once 2/3 used several types Consumers were of similar age as non-consumers Drug users had higher HbA1c vs. non-users P.Lee Managing young people with type 1 diabetes in a rave new world.2012
41 Sexual Health Non-jugemental approach to sexual activity Advice methods of avoiding pregnancy and sexually transmitted infections (STIs) Prevention of hypoglycemia during or after intercourse Advice on genital hygiene, vulvovaginal candidiasis and STIs Pre-pregnancy counceling
42 Contraception Barrier methods (condoms, diaphragms not recommended, coitus interruptus high pregnancy rate) Oral contraceptives (OCs) <35 mcg of EE not associated with cardiovascular risk, metabolic disturbances, weight gain or dyslipidemia If diabetes duration <20 yrs and no micro-/macrocomplications - any hormonal contraception may be used If diabetes duration > 20 yrs or having micro-/macrocomplications avoid Ocs, may use progestins only (magers due to pills omission) Morning after hormone pill Depot hormone injections no studies in T1D. Medroxiprogesterone decreased bone mass gain Long acting reversible contraception (IUD and implantable rod) acceptable, but no protection against STIs
43 Transition Transition is a process not an event
44 Transition to adulthood 5 milestones Completing school Leaving home Becoming financially independent Getting married Having a child And on the top manage your disease
45 Transition to adult care Danger that young people become lost in transition process and cease regular attendance to specialized services Transition should be an organized process of preparation and adaptation Pediatric team is responsible for full diabetes control screening visit before transition Provide a joint clinic with members of both pediatric and adult team Good communication, written patient care pathway and protocol, common database
46 Current methods of transfer of young people with Type 1 diabetes to adult services 229 subjects with T1D Mean age at transfer was 17.9 years (range years) High rate of clinic attendance (at least 6 monthly) 2 years pretransfer (94%), but this declined to 57% 2 years post-transfer (P < ). higher rates in clinic attendance 2 years post-transfer were seen in districts where young people had the opportunity to meet the adult diabetes consultant prior to transfer (71 vs. 29%).. Kipps et al, Diabet Med. 2002
47 Recommendations Train staff to work with young people and transition issues. Good relationship with general practitioners Children and adult services need to communicate and work together effectively. Multi-disciplinary teams to provide coordinated care A qualified psichological care is essencial in all stages of transition period Rosen et al. 2003; Department of Health 2004, 2007a; Shaw et al. 2004; Department of Health & Department for education and skills 2006; Department of Health & Department for children schools and families 2007, 2008b; Royal Australasian College of Physicians 2007; Collis et al. 2008; All Party Parliamentary Group on Autism & Allard 2009
48 Where to start from Not teach and tell Doctor tells the patient what he/she needs to know and do Doctors usually Diagnose the disease Determine the treatment Measure the outcomes But collaborate and empower Doctor and patient have a role making a decision Doctors should Description (understand the disease) Prediction Choic
49 Communicate to Negotiate Ask Listen Summarize Invite When a patient feels that you listen to him adequately, he will be more open to your suggestions
50 Motivational communication Nonjudgmental curiosity Expressing empathy (ask, listen, summarize, invite) Avoid arguing
51
52 Thank you!
INSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد
INSULIN THERAY DIABETES1 IN TYPE دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد Goals of management Manage symptoms Prevent acute and late complications Improve quality of life Avoid
More informationWhat is the role of insulin pumps in the modern day care of patients with Type 1 diabetes?
What is the role of insulin pumps in the modern day care of patients with Type 1 diabetes? Dr. Fiona Wotherspoon Consultant in Diabetes and Endocrinology Dorset County Hospital Fiona.Wotherspoon@dchft.nhs.uk
More informationEAST OF ENGLAND CHILDREN AND YOUNG PEOPLE S DIABETES NETWORK. Optimising Glycaemic Control for Children and Young People with Diabetes
EAST OF ENGLAND CHILDREN AND YOUNG PEOPLE S DIABETES NETWORK Optimising Glycaemic Control for Children and Young People with Diabetes Local diabetes teams need to take on the responsibility of ensuring
More informationInsulin Pump Therapy in children. Prof. Abdulmoein Al-Agha, FRCPCH(UK)
Insulin Pump Therapy in children Prof. Abdulmoein Al-Agha, FRCPCH(UK) aagha@kau.edu.sa Highlights Evolution of insulin pump Pumps mimics Pancreas Goals of diabetes care What lowers HbA1c Criteria for selection
More informationCandid Discussions About Diabetes and Eating Disorders, Part 1 February 14, 2018
Candid Discussions About Diabetes and Eating Disorders, Part 1 February 14, 2018 Anorexia Nervosa Calorie restriction leading to body weight less than minimally normal. Intense fear of gaining weight,
More informationEATING DISORDERS By Briana Vittorini
EATING DISORDERS By Briana Vittorini OVERVIEW What is an eating disorder? Important facts The SHOCKING truth The most common forms Beliefs about eating disorders Prevalence vs. Funding OVERVIEW Specific
More informationInsulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness
Insulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness Prepared for: Agency for Healthcare Research and Quality (AHRQ) www.ahrq.gov Outline of Material Introduction
More informationDIAGNOSIS OF DIABETES NOW WHAT?
DIAGNOSIS OF DIABETES NOW WHAT? DISCUSS GOALS FOR DIABETES CARE IDENTIFY COMMON COMPLIANCE- ADHERENCE ISSUES DESCRIBE TECHNOLOGY TO ASSIST AND / OR IMPROVE DIABETES CARE WHAT DO WE WANT OUR PATIENTS TO
More informationAdvances in Diabetes Care Technologies
1979 Advances in Diabetes Care Technologies 2015 Introduction Insulin pump use: ~ 20% - 30% of patients with T1DM < 1% of insulin-treated patients with T2DM 2007 FDA estimates ~375,000 insulin pumps for
More informationType 1 Diabetes and Eating Disorders
2/11/217 Type 1 Diabetes and Eating Disorders Marietta Stadler In type 1 diabetes (T1DM) eating disorders (ED) are a common complex problem 4, adults in the UK with T1DM 3% of women 1,2 and 7% of men 3
More informationDiabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)
Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond) 9501366-011 20110401 Objectives Understand the need for insulin pumps and CGMS in managing
More informationCGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER
CGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER Case 1: CGM use during pregnancy 29 yo G1P0000 at 10 5/7 weeks gestation presents to set
More informationEndocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh
Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research
More informationAdvances in Diabetes Care Technologies
1979 Advances in Diabetes Care Technologies 2015 Introduction Roughly 20% - 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the US FDA estimated
More informationDiabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical
Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical Practice Guideline Task Force Members Anne Peters, MD (Chair)
More informationIn general: Hypoglycemia is common in insulin treated diabetes, but may also occur in people on oral medications, especially sulfonylureas/glinides.
1 2 3 In general: Hypoglycemia is common in insulin treated diabetes, but may also occur in people on oral medications, especially sulfonylureas/glinides. 4 Answer: b and c Many alcohol containing drinks
More informationNewer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference
Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global
More informationDEMYSTIFYING INSULIN THERAPY
DEMYSTIFYING INSULIN THERAPY ASHLYN SMITH, PA-C ENDOCRINOLOGY ASSOCIATES SCOTTSDALE, AZ SECRETARY, AMERICAN SOCIETY OF ENDOCRINE PHYSICIAN ASSISTANTS ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING
More informationTUE Physician Guidelines Medical Information to Support the Decisions of TUE Committees Diabetes Mellitus DIABETES MELLITUS
DIABETES MELLITUS 1. Introduction Diabetes is a global epidemic with 415 million people affected worldwide equivalent to the total population of the USA, Canada and Mexico. In recognition of this, the
More informationUpdate in the management of childhood-onset T1DM
KDA 2018 S2 Clinical diabetes & therapeutics 1 Update in the management of childhood-onset T1DM May 4, 2018 Jae Hyun Kim, MD Seoul National University Bundang Hospital Department of Pediatrics 본발표와관련된이해관계
More informationPumps & Sensors made easy. OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University
Pumps & Sensors made easy OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University DeFronzo RA. Diabetes. 2009;58:773-795. Ominous Octet Relationship of b-cell Dysfunction and Development
More informationResources relevant for year olds
Resources relevant for 14 15 year olds Guide for healthcare professionals This guide outlines the goals of diabetes education for your 14 15 year old patients. Use this guide as part of a narrative discussion
More informationCounting the Carbs, Fat and Protein in Type 1 Diabetes Translating the Research into Clinical Practice
Welcome to Allied Health Telehealth Virtual Education Counting the Carbs, Fats and Protein in Type 1 Diabetes Translating the Research into Clinical Practice Dr Carmel Smart, PhD Senior Specialist Paediatric
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) June 2017 Review: June 2020 (earlier if required see recommendations) Bulletin 255: Insulin aspart New Formulation - Fiasp JPC Recommendations:
More informationBEST 4 Diabetes. Optimisation of insulin module
BEST 4 Diabetes Optimisation of insulin module Confidence and competence Where would you rate yourself? Why do all of our patient not achieve optimal blood glucose control? Insulin Therapy Goals and Purpose
More informationBEST 4 Diabetes. Optimisation of insulin module
BEST 4 Diabetes Optimisation of insulin module Confidence and competence Where would you rate yourself? Why do all of our patient not achieve optimal blood glucose control? Insulin Therapy Goals and Purpose
More informationClinical Evidence for Insulin Pump Therapy
Clinical Evidence for Insulin Pump Therapy 9501169-011 Objective Review the clinical evidence supporting the use of insulin pump therapy Key Points The benefits of CSII are: Improved metabolic control
More informationHypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier??
Hypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier?? Moshe Phillip Institute of Endocrinology and Diabetes National Center of Childhood Diabetes Schneider
More informationAdvances in Diabetes Care Technologies
Advances in Diabetes Care Technologies 1979 2015 Introduction Roughly 20% to 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the U.S. FDA
More informationPaolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna. Ipoglicemie e Monitoraggio Glicemico
Paolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna Ipoglicemie e Monitoraggio Glicemico Management of Hypoglycaemia.if hypoglycemia is a problem, the principles
More informationATHLETES & PRESCRIBING PHYSICIANS PLEASE READ
ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ USADA can grant a Therapeutic Use Exemption (TUE) in compliance with the World Anti- Doping Agency International Standard for TUEs. The TUE application process
More informationSponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationDiabetes Management with Continuous Glucose Monitoring & Multiple Daily Injections. Aaron Michels MD
Diabetes Management with Continuous Glucose Monitoring & Multiple Daily Injections Aaron Michels MD Outline SMBG & CGM by age group JDRF CGM Trial Sensor Augmented Insulin Pump Therapy for A1c Reduction
More informationBasics of Continuous Subcutaneous Insulin Infusion Therapy. Lubna Mirza, MD Norman Endocrinology Associates 2018
Basics of Continuous Subcutaneous Insulin Infusion Therapy Lubna Mirza, MD Norman Endocrinology Associates 2018 Preamble Roughly 20% - 30% of patients with T1DM and fewer than 1% of insulin-treated patients
More informationHeather Dacus, DO, MPH Preventive Medicine Physician Director, Bureau of Chronic Disease Control New York State Department of Health
Heather Dacus, DO, MPH Preventive Medicine Physician Director, Bureau of Chronic Disease Control New York State Department of Health Disclosure Heather Dacus has no real or perceived vested interests that
More informationPresented by Dr. Bruce Perkins, MD MPH Dr. Michael Riddell, PhD
Type 1 Diabetes and Exercise: Optimizing the Medtronic MiniMed Veo Insulin Pump and Continuous Glucose Monitoring (CGM) for Better Glucose Control 1,2 for Healthcare Professionals Presented by Dr. Bruce
More informationStandards of Care in Diabetes What's New? Veronica Brady, FNP-BC, PhD, BC-ADM,CDE Karmella Thomas, RD, LD,CDE
Standards of Care in Diabetes 2016-- What's New? Veronica Brady, FNP-BC, PhD, BC-ADM,CDE Karmella Thomas, RD, LD,CDE Terminology No longer using the term diabetic. Diabetes does not define people. People
More informationWelcome to Vancouver, BC! Best Diabetes Practices in Canada. Objectives. Our Home and Native Land. Canada and Canadian Health Care
Best Diabetes Practices in Canada Welcome to Vancouver, BC! Daniel L. Metzger, MD Pediatric Endocrinologist Objectives Overview of Canada and Canadian health care Overview of the scope of diabetes in Canada
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationOpinion 18 December 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 18 December 2013 LANTUS 100 units/ml, solution for injection in a vial B/1 vial of 10 ml (CIP: 34009 359 464 9 2)
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationNew Hires Program Canadian Diabetes Educator Certification Board Competencies Addressed
New Hires Program Canadian Diabetes Educator Certification Board Competencies Addressed Competency Pathophysiology 1.A Describes the pathophysiology and progression of all types of 1.B Distinguishes between
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More information15 th Annual DAFNE collaborative meeting Tuesday 28 th June 2016
15 th Annual DAFNE collaborative meeting Tuesday 28 th June 2016 Sponsored by: Abbott Diabetes Care and Lilly Diabetes Type 1 and exercise Royal Berkshire Hospital Centre for Diabetes and Endocrinology
More informationLOW SUGAR: CAUSES, COMPLICATIONS AND MANAGEMENT OF HYPOGLYCEMIA
LOW SUGAR: CAUSES, COMPLICATIONS AND MANAGEMENT OF HYPOGLYCEMIA Anne Leake, PhD, APRN-Rx, BC-ADM ECHO Diabetes Learning Group 3/28/2018 Objectives 1. Identify common preventable causes of hypoglycemia
More informationThe Dangers of Diabulimia. What is Type 1 Diabetes?
3/15/17 The Dangers of Diabulimia What Every Person With Type 1 Needs to Know What is Type 1 Diabetes? An auto-immune disease in which the immune system attacks itself, destroying the insulin secreting
More informationClinical Value and Evidence of Continuous Glucose Monitoring
Clinical Value and Evidence of Continuous Glucose Monitoring 9402313-012 Objective To review the clinical value and the recent clinical evidence for Professional and Personal CGM Key Points CGM reveals
More informationDiabetes Management: Current High Tech Innovations
Diabetes Management: Current High Tech Innovations How Far We ve Come in the Last 40 Years William V. Tamborlane, MD Department of Pediatrics Yale School of Medicine Disclosures I am a consultant for:
More informationWhat is a CGM? (Continuous Glucose Monitor) The Bionic Pancreas Is Coming
The Bionic Pancreas Is Coming Montana Diabetes Professional Conference October 23, 2014 H. Peter Chase, MD Professor of Pediatrics University of Colorado Barbara Davis Center Stanford: Bruce Buckingham,
More informationThis certificate-level program is non-sponsored.
Program Name: Diabetes Education : A Comprehensive Review Module 5 Intensive Insulin Therapy Planning Committee: Michael Boivin, B. Pharm. Johanne Fortier, BSc.Sc, BPh.LPh, CDE Carlene Oleksyn, B.S.P.
More informationKathleen Dunn, RN CDE Jason Pelzek, RN CDE Ksenia Tonyushkina, MD Baystate Pediatric Endocrinology June, 2018
Kathleen Dunn, RN CDE Jason Pelzek, RN CDE Ksenia Tonyushkina, MD Baystate Pediatric Endocrinology June, 2018 Ksenia Tonyushkina, MD 1 Objectives What does it mean to live with T1DM? Why exercise is important?
More informationCommissioning Policy Individual Funding Request
Commissioning Policy Individual Funding Request Continuous Glucose Monitors Prior Approval Policy Date Adopted: 13 October 2017 Version: 1718.2 Document Control Title of document Continuous Glucose Monitors
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA151 Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus This guidance was issued in
More informationDiabetes and Technology. Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE
Diabetes and Technology Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE Disclosure Speaker s Bureau: Janssan Pharmaceuticals Current Technology V-Go by Valeritas Continuous Sensors (personal
More informationApplication of the Diabetes Algorithm to a Patient
Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent
More informationTreatment guideline for adult patients with type 1 diabetes?
Treatment guideline for adult patients with type 1 diabetes? Jae Hyeon Kim Division of Endocrinology and Metabolism, Samsung Medical Center, Sungkyunkwan University School of Medicine ICDM 2014 Treatment
More informationThe Realities of Technology in Type 1 Diabetes
The Realities of Technology in Type 1 Diabetes May 6, 2017 Rosanna Fiallo-scharer, MD Margaret Frederick, RN Disclosures I have no conflicts of interest to disclose I will discuss some unapproved treatments
More informationNew basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011
New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011 Presenter Disclosure I have received the following
More informationPosition Statement of ADA / EASD 2012
Management of Hyperglycemia in Type2 Diabetes: A Patient- Centered Approach Position Statement of ADA / EASD 2012 Cause of : Type 2 diabetes Cardiovascular disorders Blindness End-stage renal failure Amputations
More information[Frida Svendsen and Jennifer Southern] University of Oxford
In adolescents with poorly controlled type 1 diabetes mellitus, could a bionic, bihormonal pancreas provide better blood glucose control than continuous subcutaneous insulin infusion therapy? [Frida Svendsen
More informationInjecting Insulin into Out Patient Practice
Injecting Insulin into Out Patient Practice Kathleen Colleran, MD Associate Professor UNMHSC 4/22/10 Overview Natural history of Type 2 diabetes Reasons clinicians are reluctant to start insulin therapy
More informationUpdate on Continuous Glucose Monitoring (CGM) Technology in Diabetes. Elena Toschi, MD November 12, 2016
Update on Continuous Glucose Monitoring (CGM) Technology in Diabetes Elena Toschi, MD November 12, 2016 Presenter Disclosure Information Elena Toschi, MD No financial disclosure Objectives: Use of CGM
More informationJenaca Beagley, MSN, APRN, NP-C, CDE Michelle Smith, MSN, APRN, NP-C
Jenaca Beagley, MSN, APRN, NP-C, CDE Michelle Smith, MSN, APRN, NP-C 1 Basic review of Type 1 diabetes Pathophysiology Standards of medical care Overview of Eating Disorders ED-DMT1 Who is at risk for
More informationUNCOVERING THE BENEFITS OF THE ACCU- CHEK BOLUS ADVISOR MICHAEL PORTER CDE
UNCOVERING THE BENEFITS OF THE ACCU- CHEK BOLUS ADVISOR MICHAEL PORTER CDE 1 LEARNING OBJECTIVES By the end of this session participants should be able to understand: The benefits of bolus advisors The
More informationComparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary
Number 14 Effective Health Care Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary Background and Key Questions
More informationDAFNE (Dose Adjustment For Normal Eating)
DAFNE (Dose Adjustment For Normal Eating) Promoting the Expert Patient Professor David McIntyre Mater Health Services and University of Queensland Brisbane AUSTRALIA DAFNE and OzDAFNE Outline Context of
More informationReport Reference Guide
Report Reference Guide How to use this guide Each type of CareLink report and its components are described in the following sections. Report data used to generate the sample reports was from sample patient
More informationFrom Childhood to Adulthood: Young Adult Transitions in Diabetes Care
From Childhood to Adulthood: Young Adult Transitions in Diabetes Care Lori Laffel, MD, MPH Chief, Pediatric, Adolescent and Young Adult Section Investigator, Genetics and Epidemiology Section Joslin Diabetes
More informationAnneli, Martina s daughter In better control with her pump since 2011 MY CHILD HAS TYPE 1 DIABETES
Anneli, Martina s daughter In better control with her pump since 2011 MY CHILD HAS TYPE 1 DIABETES Many parents whose child is diagnosed with Type 1 diabetes wonder: Why is this happening to my child?
More information8/5/2015. Jean Corrigan. Susan Ruggiero RN, MA, CDE. Sheila Dennehy. Edith Fiore RN, MS, CDE RN, MS, CDE MS, RN, CPNP, CDE.
8/5/2015 Disclosure to Participants Notice of Requirements For Successful Completion Please refer to learning goals and objectives Learners must attend the full activity and complete the evaluation in
More informationSHARED CARE GUIDELINE ON THE USE OF FIASP FOR THE MANAGEMENT OF TYPE 1 DIABETES IN ADULTS
SHARED CARE GUIDELINE ON THE USE OF FIASP FOR THE MANAGEMENT OF TYPE 1 DIABETES IN ADULTS INDICATION Fiasp is indicated for the treatment of diabetes mellitus in adults. Special Note: DMAG has approved
More informationExercise Prescription in Type 1 Diabetes
Exercise Prescription in Type 1 Diabetes Michael Riddell, PhD Professor, Muscle Health Research Centre and School of Kinesiology & Health Science, York University Senior Scientist, LMC Diabetes & Endocrinology,
More informationThe artificial pancreas: the next step in connectivity and digital treatment of type 1 diabetes
The artificial pancreas: the next step in connectivity and digital treatment of type 1 diabetes Roman Hovorka PhD FMedSci University of Cambridge, UK Duality of interest declaration Advisory Panel: Research
More informationState of California Health and Human Services Agency Department of Health Care Services
State of California Health and Human Services Agency Department of Health Care Services JENNIFER KENT Director EDMOND G. BROWN JR Governor DATE: N.L.: 03-0317 Index: Benefits TO: ALL COUNTY CALIFORNIA
More informationDiabetes & Eating Disorders: A Complicated Relationship. Quinn Nystrom, M.S. Jenaca Beagley A.P.R.N., C.D.E.
Diabetes & Eating Disorders: A Complicated Relationship Quinn Nystrom, M.S. Jenaca Beagley A.P.R.N., C.D.E. Prevalence of Eating Disorders 75% of American women are dissatisfied with their appearance.
More informationTYPE 1 DIABETES AND EXERCISE. Mark W Savage
TYPE 1 DIABETES AND EXERCISE Mark W Savage Acknowledgments Slides with a blue background are cropped and courtesy of both Eli Lilly and Company, and Dr Ian Gallen FRCP Consultant Diabetologist, Royal Berkshire
More informationPROTOCOL FOR HYBRID CLOSED LOOP TECHNOLOGY
PROTOCOL FOR HYBRID CLOSED LOOP TECHNOLOGY Situations Requiring Special Consideration and Resource Documents Second Edition MiniMed 67G System Medical Education TABLE OF CONTENTS A PROTOCOL FOR HYBRID
More informationWILL AGE 5 4/16/19. Type 1 Diabetes & Eating Disorders: Navigating the Complexities of Provider- Patient Communication. Disclosure to Participants
Type 1 Diabetes & Eating Disorders: Navigating the Complexities of Provider- Patient Communication Quinn Nystrom, M.S. Speaker, Author & Diabetes Advocate National Diabetes Ambassador - Center for Change
More informationEffective Health Care Program
Comparative Effectiveness Review Number 57 Effective Health Care Program Methods for Insulin Delivery and Glucose Monitoring: Comparative Effectiveness Executive Summary Background Diabetes mellitus is
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationPREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS)
PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS) Pathways for Future Treatment and Management of Diabetes H. Peter Chase, MD Carousel of Hope Symposium Beverly Hilton, Beverly
More informationFamily Teamwork and Type 1 diabetes. Barbara J. Anderson, Ph.D. Professor of Pediatrics Baylor College of Medicine Houston, TX
Family Teamwork and Type 1 diabetes Barbara J. Anderson, Ph.D. Professor of Pediatrics Baylor College of Medicine Houston, TX Lessons from Research: What are the family factors that predict optimal adherence
More informationRole of Academia In Achieving Targets in Diabetes Care
Role of Academia In Achieving Targets in Diabetes Care Disclosures Member of NovoNordisk, Lilly, Metavention, Sanofi, and Janssen Diabetes Advisory Boards Role of Academia in Discovering New Treatments
More information1. Continuous Glucose Monitoring
1. Continuous Glucose Monitoring 1. Physiology of interstitial fluid glucose 2. Comparison of CGM and self-monitored blood glucose (SMBG) data 3. Insulin dosing indication in BGM vs. CGM & the FDA 4. Protection
More informationHOW CAN WE PREVENT RECURRENT-DKA?
pinterest HOW CAN WE PREVENT RECURRENT-DKA? Birgit Rami-Merhar DKA is not only a problem at the onset of T1D T1D-children at risk for recurrent DKA: 1-10%/patient/year (ISPAD 2014) mortality rate from
More informationQUESTION 4. WHAT CLINICAL DATA ARE CURRENTLY AVAILABLE TO SUPPORT EXPANDED CGM COVERAGE BY PAYERS AS PERTAINS TO QUESTIONS 1 AND 3?
500 1 QUESTION 4. WHAT CLINICAL DATA ARE CURRENTLY AVAILABLE TO SUPPORT EXPANDED CGM COVERAGE BY PAYERS AS PERTAINS TO QUESTIONS 1 AND 3? WHAT ADDITIONAL DATA ARE NEEDED? AACE/ACE CGM Consensus Conference:
More informationProfessional development requirements for delivery of Lift for Life
Professional development requirements for delivery of Lift for Life Exercise Professionals can deliver the Lift for Life program beyond the initial two year approval period if they are to meet the following
More informationΑναγκαιότητα και τρόπος ρύθμισης του διαβήτη στους νοσηλευόμενους ασθενείς
Αναγκαιότητα και τρόπος ρύθμισης του διαβήτη στους νοσηλευόμενους ασθενείς Αναστασία Θανοπούλου Επίκουρη Καθηγήτρια Β Παθολογικής Κλινικής Πανεπιστημίου Αθηνών Διαβητολογικό Κέντρο, Ιπποκράτειο Νοσοκομείο
More informationTHE CURRENT APPROACH TO T1D IN CHILDREN
THE CURRENT APPROACH TO T1D IN CHILDREN Dina Panagiotopoulos, MD, FRCPC Associate Professor, Department of Pediatrics University of British Columbia Endocrinologist, BC Children s Hospital CFRI & CDA Clinician
More informationDo Now: Write Down 5 Traits for Female models and 5 Traits for Male models
Do Now: Write Down 5 Traits for Female models and 5 Traits for Male models Female Models... Common Traits Male Models... Common Traits Beauty Pressure Body Image In one minute, write the most important
More informationUpdates in Diabetes Technology
Updates in Diabetes Technology Jessica Kirk, MSN, RN, CPN, CDE Nurse Manager, Endo ECHO No disclosures Disclosures 1 Objectives Distinguish patients appropriate for continuous glucose monitoring and insulin
More informationMaking the Most of Continuous Glucose Monitoring
Making the Most of Continuous Glucose Monitoring Gary Scheiner MS, CDE Owner & Clinical Director Integrated Diabetes Services LLC Wynnewood, PA AADE 2014 Diabetes Educator of the Year gary@integrateddiabetes.com
More informationInsulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children
Insulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children December 2008 This technology summary is based on information available at the time of research and a limited literature
More informationPlacename CCG. Policies for the Commissioning of Healthcare
Placename CCG Policies for the Commissioning of Healthcare Policy for the funding of insulin pumps and continuous glucose monitoring devices for patients with diabetes 1 Introduction 1.1 This document
More informationComplete Comprehensive Diabetes Educator modules available at CCCEP File #: I-P (Expires: Mar.
CDE Preparation Program Topics (Accredited by CCCEP for 0.5 CEUs/Module section Total = 20 CEUs) Module 1 Pathophysiology of Diabetes 5 segments Module 2 Diabetes and Nutrition 5 segments Module 3 Medications
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationPump Therapy - Simple, Proven, and Well Accepted
Pump Therapy - Simple, Proven, and Well Accepted Innovating for life. Pump therapy is simple for providers and patients Healthcare Providers Simple outpatient procedure: Low burden and cost to transition
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationINSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION
INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION Jaiwant Rangi, MD, FACE Nov 10 th 2018 DISCLOSURES Speaker Novo Nordisk Sanofi-Aventis Boheringer Ingleheim Merck Abbvie Abbott
More informationHandbook of Insulin Therapies
Handbook of Insulin Therapies Winston Crasto Janet Jarvis Melanie J. Davies Handbook of Insulin Therapies Winston Crasto George Eliot Hospital NHS Trust, Nuneaton United Kingdom Janet Jarvis Leicester
More information